This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The microtubule targeting agents plinabulin, docetaxel, and vinblastine interrupt MT polymerization by altering both MT conformation and binding free energy of the neighboring tubulin subunits. Abstract The natural products plinabulin, docetaxel, and vinblastine are microtubule targeting agents (MTAs). They have been used alone or in combination in cancer treatment.
This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from October 2022. Last month, IQVIA quietly released a fascinating new report on discount cards. (Link below.) The research was sponsored by the Association for Accessible Medicines (AAM).
This chart shows the pharmaceutical companies with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.
Osteoporosis, a disease that causes the bones to become brittle and porous, can significantly impact a person’s quality of life. It is the most common bone disease in the world, impacting about 54 million people — but many people are not diagnosed with osteoporosis until after a fracture occurs.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bayesian methods have been playing a key role in transforming clinical research, and Bayesian topics are frequently featured in Cytel’s Perspectives on Enquiry and Evidence. Our new ebook features a set of articles exploring various topics related to Bayesian statistical methods.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from September 2022. During Friday’s webinar, I’ll be sharing my updated thoughts about the IRA’s impact on manufacturers, Part D plans, and patient behavior. By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. 117-169).
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from September 2022. During Friday’s webinar, I’ll be sharing my updated thoughts about the IRA’s impact on manufacturers, Part D plans, and patient behavior. By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. 117-169).
This chart shows the pharmaceutical companies with the most patents in New Zealand. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical companies have the most drug patents in New Zealand? appeared first on DrugPatentWatch - Make Better Decisions.
The ChEMBL Team heads off soon on their Christmas holidays! Before we leave, we would like to remember some highlights of 2022 and share some outlook for the next year! 2022 was an extraordinary year for the UK and also for the ChEMBL Team! It was a year of celebrations, farewells, and new beginnings. The ChEMBL team underwent major personnel changes in 2022 , with Anna and Patricia leaving the team, and Barbara, Eloy and Fiona taking on new roles within the ChEMBL leadership team. 2022 was a ye
3D adult stem cell (ASC)-derived tumor organoids can enhance the translatability of drug discovery data, especially in combination with high content imaging (HCI). In this blog post, we explore how the pairing of these two technologies allows researchers to develop highly comprehensive and predictive data that can enable better decisions earlier in drug discovery, while improving the translatability of the most promising lead compounds.
This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Outlook 2023. In the four months since I published the article below, the issues with alternative funding programs have hit the mainstream press. Check out last week's article from Kaiser Health News: Employers Use Patient Assistance Programs to Offset Their Own Costs.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Annual Drug Patent Expirations for VARUBI Varubi is a drug marketed by Tersera and is included in two NDAs. It is available from one supplier. There are nine patents protecting…. The post New patent expiration for Tersera drug VARUBI appeared first on DrugPatentWatch - Make Better Decisions.
At Antidote, we believe that all members of society should be equally represented — especially when it comes to medical research. Historically, racial and ethnic minorities have been under-represented in the clinical trial space , and continue to face challenges when trying to access healthcare today.
As the research community continues to seek clinical trial efficiencies designed to bring therapies to patients faster, more governing bodies are pushing for single institutional review board (single IRB) review as one way to streamline efforts. To better understand what sIRB review requirements mean for sites and sponsors, it’s important to first understand what an single IRB is and how it works.
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Outlook 2023. ICYMI, the Health Resources and Services Administration (HRSA) finally got tired of my Freedom of Information Act (FOIA) requests. Shortly after I published the article below, HRSA posted public data about 340B covered entity purchases on its website.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Annual Drug Patent Expirations for XYOSTED+%28AUTOINJECTOR%29 Xyosted (autoinjector) is a drug marketed by Antares Pharma Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Antares Pharma drug XYOSTED (AUTOINJECTOR) appeared first on DrugPatentWatch - Make Better Decisions.
When evaluating the efficacy of a candidate investigational therapy, a standard clinical trial paradigm is to conduct a two-arm randomized trial, typically evaluating that therapy against a control arm. And if multiple therapies are being evaluated against the same disease, there may be multiple parallel two-arm trials. However, this creates redundancies, wasting time and resources.
Digital health products are widely used for the prevention, diagnosis, treatment, and management of health and disease. The introduction of digital medicines—and, more recently, digital therapeutics (DTx)—has begun to influence the treatment and management of certain diseases, both by consumers and by clinicians. Driven by advances in technology and increased acceptance of telehealth, digital medicines and DTx are poised to become an integral part of the healthcare model.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Click here to see the original post and comments from August 2022. Over the weekend, the U.S. Senate passed a massive overhaul of the Medicare Part D program. If passed into law, these changes will have many unintended consequences , but will not address the warped incentives baked into our current rebate system.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. It is available from one supplier. There are twelve patents…. The post New patent for Zogenix Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.
As we approach the end of 2022, it could not be a better time to go through some important and fascinating breakthroughs from the year that propelled us toward significant advancements within the life sciences space. The future is now, and innovative technology has changed the world, forcing the Biotech/Pharma and Med-Device sectors to transform their process.
Announcing Keystone Symposia's new Chief Scientific Officer, Dr. Terry Sheppard, formerly founding Chief Editors at Nature Chemical Biology, and the retirement of current CSO Dr. Thale Jarvis.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Annual Drug Patent Expirations for VANCOMYCIN+HYDROCHLORIDE Vancomycin Hydrochloride is a drug marketed by Akorn, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Strides Pharma, Watson Labs, Aspiro, Emcure Pharms…. The post New patent for Xellia Pharms drug VANCOMYCIN HYDROCHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.
Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinical trial advancement. Worldwide Clinical Trials has partnered with the leading medical genetics company, Invitae , making Worldwide the first CRO to use Invitae’s Explorer tool.
The post-pandemic clinical trial landscape has paved way for the integration of technology, data analytics, and digitization to facilitate all aspects of trial management from patient identification and recruitment to […]. The post What is eCOA and ePRO? appeared first on ProRelix Research.
We sat down for a Q&A with investors in a conversation moderated by Shareholder Nathan Reese. Watch our recording of the webcast here. The post Shareholder Q&A appeared first on Predictive Oncology.
Annual Drug Patent Expirations for KLISYRI Klisyri is a drug marketed by Almirall and is included in one NDA. It is available from one supplier. There are seven patents protecting…. The post New patent for Almirall drug KLISYRI appeared first on DrugPatentWatch - Make Better Decisions.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
100 
Let's personalize your content